Cardiovascular Drugs Practice Questions

Q: Which of the following statements best describes long-acting nitrate preparations?

Tolerance often develops. **Explanation:** **1. Why Option A is Correct:** Nitrate tolerance (tachyphylaxis) is a well-documented phenomenon where the therapeutic effect diminishes with continuous exposure. The underlying mechanism involves **oxidative stress**, leading to the depletion of **sulfhydryl (-SH) groups** required for the conversion of nitrates to Nitric Oxide (NO) and the inactivation of mitochondrial aldehyde dehydrogenase. To prevent this, a **"nitrate-free interval"** of 8–12 hours (usually at night) is clinically mandated to restore tissue sensitivity. **2. Why the Other Options are Incorrect:** * **Option B:** The mechanism of action of nitrates (cGMP-mediated vasodilation) is independent of beta-receptors. In fact, beta-blockers are often combined with nitrates to prevent reflex tachycardia. * **Option C:** Sublingual nitrates cause a rapid, high-peak plasma concentration leading to immediate meningeal vasodilation and "throbbing" headaches. Transdermal patches provide a slow, sustained release, making them *less* likely to cause acute, severe headaches compared to the sublingual route. * **Option D:** Oral nitrates undergo extensive **first-pass metabolism** in the liver (especially Nitroglycerin), making them significantly *less* potent and slower-acting than sublingual preparations, which bypass the liver and enter systemic circulation directly. **Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Sublingual Nitroglycerin (GTN) is the DOC for acute anginal attacks; Isosorbide mononitrate is preferred for prophylaxis due to 100% bioavailability. * **Contraindication:** Never co-administer nitrates with **Sildenafil (PDE-5 inhibitors)** as it can lead to catastrophic hypotension. * **Storage:** GTN is volatile and light-sensitive; it should be stored in dark glass containers.

Q: Gemfibrozil produces hypolipidemic action by?

Increasing activity of lipoprotein lipase. Gemfibrozil belongs to the Fibrate class of hypolipidemic drugs. Its primary mechanism of action involves the activation of Peroxisome Proliferator-Activated Receptor-alpha (PPAR-α), a nuclear receptor [1]. 1. **Why Option A is Correct:** Activation of PPAR-α by Gemfibrozil leads to the increased transcription of the gene for Lipoprotein Lipase (LPL) [1]. LPL is the key enzyme responsible for the hydrolysis of triglycerides in VLDL and chylomicrons. By increasing LPL activity and down-regulating inhibitor proteins like apo C-III, Gemfibrozil significantly enhances the clearance of triglyceride-rich lipoproteins, making it the drug of choice for Hypertriglyceridemia [1]. 2. **Why Other Options are Incorrect:** * **Option B:** While fibrates do slightly decrease VLDL production, their *primary* and most potent action is the enhancement of LPL-mediated clearance [1]. * **Option C:** This is the primary mechanism of Statins (HMG-CoA reductase inhibitors) and PCSK9 inhibitors, which upregulate LDL receptors to lower serum LDL cholesterol. * **Option D:** This describes the mechanism of Bile Acid Sequestrants (e.g., Cholestyramine), which prevent bile acid reabsorption, forcing the liver to convert more cholesterol into bile acids. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Effect:** Fibrates are the most effective drugs for lowering Triglycerides (TGs) and increasing HDL [1]. * **Adverse Effects:** Myopathy and Rhabdomyolysis (risk increases significantly when combined with Statins) [2], [3]. * **Contraindication:** Gemfibrozil should be avoided in patients with Gallstones (cholelithiasis) because it increases biliary cholesterol excretion. * **Drug Interaction:** Gemfibrozil inhibits the glucuronidation of Statins, leading to increased statin plasma levels and toxicity.

Q: Digoxin can accumulate to toxic levels in patients with?

Renal insufficiency. **Explanation:** The primary mechanism for the elimination of **Digoxin** is renal excretion. Approximately 60-80% of the drug is excreted unchanged in the urine via glomerular filtration and tubular secretion (mediated by P-glycoprotein). 1. **Why Renal Insufficiency is Correct:** Since Digoxin has a narrow therapeutic index (0.5–2 ng/mL) and is primarily cleared by the kidneys, any decrease in the Glomerular Filtration Rate (GFR) significantly increases its half-life (normally 36–40 hours). In patients with renal failure, the drug accumulates rapidly, leading to life-threatening digitalis toxicity. 2. **Why Other Options are Incorrect:** Digoxin undergoes minimal hepatic metabolism. Therefore, conditions like **Chronic Hepatitis** or **Advanced Cirrhosis** do not significantly alter its clearance. Similarly, **Chronic Pancreatitis** affects exocrine/endocrine functions of the pancreas but has no physiological role in the pharmacokinetics of Digoxin. **High-Yield Clinical Pearls for NEET-PG:** * **Hypokalemia:** This is the most important predisposing factor for Digoxin toxicity because K+ and Digoxin compete for the same binding site on the Na+/K+-ATPase pump. * **Drug Interactions:** Drugs like **Quinidine, Verapamil, and Amiodarone** reduce the renal clearance of Digoxin and can precipitate toxicity. * **ECG Findings:** The earliest sign of toxicity is often PVCs; the most characteristic sign is "Reverse Tick" ST-segment depression; the most specific arrhythmia is **Atrial Tachycardia with AV block**. * **Antidote:** Digoxin-specific antibody fragments (**DigiFab/Digibind**).

Q: Dopamine given in acute CHF does NOT act on which of the following receptors?

Alpha 1 receptors. **Explanation:** The pharmacological action of Dopamine is uniquely **dose-dependent**. To understand why Alpha-1 receptors are the correct answer in the context of acute Congestive Heart Failure (CHF), we must look at the therapeutic goals and dose ranges: 1. **Low Dose (0.5–2 µg/kg/min):** Acts primarily on **D1 receptors** (Option B) located in the renal, mesenteric, and coronary beds. This causes vasodilation and increases renal blood flow (Option A), promoting diuresis. 2. **Intermediate Dose (2–10 µg/kg/min):** Acts primarily on **Beta-1 receptors** (Option C). This increases myocardial contractility (positive inotropy) and cardiac output, which is the primary therapeutic goal in acute CHF. 3. **High Dose (>10 µg/kg/min):** Acts on **Alpha-1 receptors** (Option D), causing systemic vasoconstriction. **Why Alpha-1 is the correct answer:** In the management of acute CHF, the goal is to improve cardiac output and reduce afterload. Activating Alpha-1 receptors causes peripheral vasoconstriction, which increases afterload and myocardial oxygen demand, potentially worsening heart failure. Therefore, Dopamine is titrated to "inotropic doses" (Beta-1) and not "pressor doses" (Alpha-1) in this specific clinical setting. **Clinical Pearls for NEET-PG:** * **Dopamine vs. Dobutamine:** Dobutamine is often preferred in CHF because it has more prominent Beta-1 effects and lacks the Alpha-1 mediated vasoconstriction seen with high-dose Dopamine. * **Fenoldopam:** A selective D1 agonist used in hypertensive emergencies to maintain renal perfusion. * **Renal Dose Myth:** Recent evidence suggests the "renal dose" of dopamine does not significantly improve outcomes in acute renal failure, though it remains a high-yield exam concept.

Q: Which of the following drugs is NOT used in the management of pulmonary hypertension?

Alpha blocker. ### Explanation The management of Pulmonary Arterial Hypertension (PAH) focuses on reducing pulmonary vascular resistance through specific pathways: the **Nitric Oxide pathway**, the **Endothelin pathway**, and the **Prostacyclin pathway**. **Why Alpha Blockers are NOT used:** Alpha-blockers (like Prazosin) act primarily on peripheral $\alpha_1$ receptors to cause systemic vasodilation. They do not have a selective or significant effect on the pulmonary vasculature. Using them in PAH can lead to systemic hypotension without effectively lowering pulmonary artery pressure, potentially worsening the patient's hemodynamic status. **Analysis of Other Options:** * **Calcium Channel Blockers (CCBs):** High-dose CCBs (e.g., Nifedipine, Diltiazem, Amlodipine) are the first-line treatment for a small subset of patients who show a positive response during **Vasoreactivity Testing** (usually with inhaled Nitric Oxide). * **Endothelin Receptor Antagonists (ERAs):** Drugs like **Bosentan** (non-selective), **Ambrisentan**, and **Macitentan** (selective $ET_A$) block the potent vasoconstrictor effects of endothelin-1, which is elevated in PAH. * **Prostacyclins:** PAH is characterized by a deficiency of prostacyclin ($PGI_2$). Synthetic analogs like **Epoprostenol** (IV), **Treprostinil**, and **Iloprost** act as potent pulmonary vasodilators and inhibitors of platelet aggregation. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** For PAH, the specific choice depends on the functional class, but **Sildenafil** (PDE-5 inhibitor) is frequently used. * **Bosentan Side Effect:** It is known for **hepatotoxicity** (requires monthly LFTs) and is highly **teratogenic**. * **Riociguat:** A Soluble Guanylate Cyclase (sGC) stimulator used in PAH and chronic thromboembolic pulmonary hypertension (CTEPH). * **Selexipag:** An oral selective $IP$ prostacyclin receptor agonist.

Q: All of the following antihypertensive drugs increase plasma renin activity except?

Clonidine. **Explanation:** The regulation of **Plasma Renin Activity (PRA)** is primarily governed by the sympathetic nervous system (via $\beta_1$ receptors on juxtaglomerular cells), renal baroreceptors, and feedback loops involving Angiotensin II. **1. Why Clonidine is the correct answer:** Clonidine is a **centrally acting $\alpha_2$ agonist**. It stimulates $\alpha_2$ receptors in the nucleus tractus solitarius, leading to a decrease in sympathetic outflow from the brain. This reduction in sympathetic tone results in **decreased stimulation of $\beta_1$ receptors** in the kidney, thereby **inhibiting renin release**. Consequently, Clonidine (along with Methyldopa) decreases PRA. **2. Why the other options are incorrect:** * **Hydralazine (Vasodilator):** Causes significant peripheral vasodilation, leading to a drop in blood pressure. This triggers a potent **reflex sympathetic activation**, which stimulates $\beta_1$ receptors to increase renin release. * **Nifedipine (Calcium Channel Blocker):** Similar to other dihydropyridines, it causes vasodilation and a subsequent **reflex increase in sympathetic activity**, which raises PRA. * **Captopril (ACE Inhibitor):** By blocking the conversion of Angiotensin I to Angiotensin II, it removes the **negative feedback** that Angiotensin II normally exerts on renin release. This leads to a compensatory (reactive) increase in PRA. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs that Decrease PRA:** $\beta$-blockers (e.g., Propranolol), Centrally acting drugs (Clonidine, Methyldopa), and Direct Renin Inhibitors (Aliskiren—though Aliskiren decreases *activity*, it actually increases renin *concentration*). * **Drugs that Increase PRA:** Diuretics, ACE inhibitors, ARBs, CCBs, and direct vasodilators. * **Clonidine Withdrawal:** Abrupt cessation can lead to a **rebound hypertensive crisis** due to a sudden surge in catecholamines.

Question 1

Which of the following statements best describes long-acting nitrate preparations?

Accepted Answer

Tolerance often develops

Answer

Their effect can be blocked by high doses of beta selective inhibitors

Answer

Transdermal patches are more likely to be associated with headaches than are sublingual nitrates

Answer

Oral preparations are more effective than sublingual ones

Question 2

Why are statins typically administered at night?

Accepted Answer

HMG-CoA reductase activity exhibits its peak during midnight.

Answer

Statins achieve maximum absorption at night.

Answer

The potency of statins is enhanced during the night.

Answer

It is more convenient for patients to remember to take them at night.

Question 3

Which of the following drugs is used for the management of Supraventricular tachycardia?

Accepted Answer

Adenosine

Answer

Amiodarone

Answer

Naloxone

Answer

Calcium gluconate

Question 4

Gemfibrozil produces hypolipidemic action by?

Accepted Answer

Increasing activity of lipoprotein lipase

Answer

Decreased production of VLDL

Answer

Increase LDL receptors on hepatocytes

Answer

Increased conversion of cholesterol to bile acids

Question 5

A patient on ACE inhibitors developed a rash. What is the true statement regarding this situation?

Accepted Answer

The drug may be the cause, and discontinuation may improve the skin condition.

Answer

High-dose steroids are needed initially.

Answer

ACE inhibitors are safe and cannot lead to skin eruptions.

Answer

The drug may be the cause, but discontinuation is not required.

Question 6

A patient with Prinzmetal's angina is treated with isosorbide mononitrate. What is the mechanism of action of nitrates in this condition?

Accepted Answer

Endothelium-independent coronary vasodilation

Answer

Reduced cardiac contractility

Answer

Increased left ventricular end diastolic volume

Answer

Decreased diastolic perfusion pressure

Question 7

Digoxin can accumulate to toxic levels in patients with?

Accepted Answer

Renal insufficiency

Answer

Chronic hepatitis

Answer

Advanced cirrhosis

Answer

Chronic pancreatitis

Question 8

Dopamine given in acute CHF does NOT act on which of the following receptors?

Accepted Answer

Alpha 1 receptors

Answer

Receptors present on renal blood vessels

Answer

D1 receptors

Answer

Beta 1 receptors

Question 9

Which of the following drugs is NOT used in the management of pulmonary hypertension?

Accepted Answer

Alpha blocker

Answer

Calcium channel blocker

Answer

Endothelin receptor antagonist

Answer

Prostacyclin

Question 10

All of the following antihypertensive drugs increase plasma renin activity except?

Accepted Answer

Clonidine

Answer

Hydralazine

Answer

Nifedipine

Answer

Captopril

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?